When used long term, the autologous vaccine vitespen shows promise for adjuvant treatment of early-stage disease in patients with renal cell carcinoma. Medscape Medical News
In this Expert Interview, Lisa Carey, MD, discusses the biologic differences that underlie differences in breast tumor behavior and outcomes. Medscape Hematology-Oncology
Advances in understanding the biology of myelodysplastic syndromes and the role of new and emerging treatment options are reviewed in this summary from ASH 2007. Medscape Hematology-Oncology
Read highlights from ASH 2007 about advances in the treatment of multiple myeloma in the newly diagnosed and relapsed disease settings. Medscape Hematology-Oncology
Identify the nonsurgical strategies for the management of patients with HCC, including targeted therapies as single agents and in combination with standard chemotherapies, and review novel approaches for assessing treatment progress.
Various techniques for regional chemotherapy are able to achieve 3- to 10-times higher concentrations of the cytostatic agent at the tumor than traditional chemotherapy and increased survival in patients with platinum-refractory recurrent ovarian cancer. Medscape Medical News
Dose intensification of chemotherapy should now be abandoned as a strategy, because there is no benefit but markedly more toxicity with this approach. Medscape Medical News
In his first video blog for Medscape Urology, Dr. Culley Carson discusses an article recently published in the New England Journal of Medicine on quality of life in prostate cancer survivors. Carson on Urology
